ストックスクリーナーアプリを入手
23.99
1.23%
0.36
前日終値:
$23.63
開ける：
$23.92
24時間の取引高:
2,685
Relative Volume:
0.00
時価総額：
$864.08M
収益：
$13.00M
当期純損益:
$-68.87M
株価収益率:
-10.77
EPS:
-2.2276
ネットキャッシュフロー:
$-76.68M
1週間 パフォーマンス:
+0.29%
1か月 パフォーマンス:
-2.69%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$23.92
$23.99
1週間の範囲:
$23.10
$25.49
52週間の値動き範囲:
$13.88
$33.20
Evommune Inc Stock (EVMN) Company Profile
Compare EVMN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
23.99 | 870.20M | 13.00M | -68.87M | -76.68M | -2.2276 |
VRTX
Vertex Pharmaceuticals Inc
|
425.76 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
704.35 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
800.81 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.69 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
305.58 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-07 | 再開されました | Oppenheimer | Outperform |
| 2026-01-22 | 開始されました | Oppenheimer | Outperform |
| 2026-01-08 | 開始されました | Raymond James | Strong Buy |
| 2026-01-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-12-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-12-01 | 開始されました | Evercore ISI | Outperform |
| 2025-12-01 | 開始されました | Leerink Partners | Outperform |
| 2025-12-01 | 開始されました | Morgan Stanley | Overweight |
| 2025-12-01 | 開始されました | William Blair | Outperform |
すべてを表示
Evommune Inc (EVMN) 最新ニュース
Certain Rights of Evommune, Inc. are subject to a Lock-Up Agreement Ending on 5-MAY-2026. - marketscreener.com
Wall Street Zen Downgrades Evommune (NYSE:EVMN) to Sell - MarketBeat
Stifel Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $54 - Moomoo
Evommune (NYSE:EVMN) Coverage Initiated by Analysts at Stifel Nicolaus - MarketBeat
Stifel initiated coverage on Evommune with a new price target - Quantisnow
Stifel Initiates Evommune(EVMN.US) With Buy Rating, Announces Target Price $54 - Moomoo
Evommune and BillionToOne climb on trading debut - MSN
Evommune surges on mid-stage trial win for eczema therapy - MSN
Evommune, Inc. (NYSE:EVMN) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Evommune, Inc.'s (NYSE:EVMN) Lock-Up Period To Expire on May 5th - MarketBeat
[EFFECT] Evommune, Inc. SEC Filing - Stock Titan
Evommune’s EVO756 Phase 2b Trial: An Emerging Catalyst in Atopic Dermatitis - TipRanks
Evommune (NYSE: EVMN) registers 4.49M shares for resale by investors - Stock Titan
EVMN Options Chain — NYSE:EVMN - TradingView
Oppenheimer Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Evommune, Inc. Common Stock (NY: EVMN - FinancialContent
EVMN SEC FilingsEVOMMUNE INC 10-K, 10-Q, 8-K Forms - Stock Titan
Evommune Shelf Registration Raises Dilution Questions After Strong Share Gains - Sahm
EVMN Evommune reports wider Q4 2025 loss than analyst projections, shares dip modestly on soft quarterly earnings.Market Hype Signals - UBND thành phố Hải Phòng
Evommune (EVMN) details 2026 director votes and CEO pay in proxy - Stock Titan
Why is Evommune (EVMN) stock going up today (Institutional Selling) 2026-04-20AI Signals - Cổng thông tin điện tử Tỉnh Sơn La
Evommune (EVMN) Chief Scientific Officer awarded 69,315 stock options at $26.77 - Stock Titan
Evommune (EVMN) grants 73,892 stock options to development chief - Stock Titan
[Form 4] Evommune, Inc. Insider Trading Activity - Stock Titan
Evommune (EVMN) grants CFO 98,946 options at $26.77 strike - Stock Titan
Evommune (EVMN) grants 115,279 stock options to chief legal officer - Stock Titan
Evommune (EVMN) CEO Luis C. Pena receives 291,420 stock option grant - Stock Titan
Evommune Incprospectus filed for resale of up to 4.5 million shares of Evommune common stock by selling stockholdersSEC filing - marketscreener.com
Evommune (NYSE: EVMN) investors file to resell 4.49M previously issued shares - Stock Titan
Evommune stock price target reaffirmed at $50 by H.C. Wainwright - Investing.com South Africa
H.C. Wainwright Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Velan Capital Investment Management LP's Evommune Inc(EVMN) Holding History - GuruFocus
Evommune Makes Case For MRGPRX2 Inhibition in Migraine - Citeline News & Insights
MRGPRX2: A Novel Target in Migraine Treatment – EVO756’s Potential in Migraine Prophylaxis Explained - Minichart
William Blair Maintains Evommune(EVMN.US) With Buy Rating - Moomoo
Evommune: Differentiated MRGPRX2 Strategy and Upcoming EVO756 Phase IIb Readout Support Buy Rating - TipRanks
Evommune Spotlights EVO756 as Novel Preventive Migraine Therapy - TipRanks
Evommune (EVMN) advances oral MRGPRX2 migraine drug EVO756 toward Phase 2b - Stock Titan
RBC Capital Reaffirms Their Buy Rating on Evommune, Inc. (EVMN) - The Globe and Mail
Evommune (NYSE:EVMN) Stock Price Down 7.2%Here's Why - MarketBeat
Evommune's Chronic-Hives Drug May See Wider Use If Trial Succeeds, RBC Says - marketscreener.com
Today's Analyst Rating Update for EVMN: Maintained at Outperform - GuruFocus
Evommune (NYSE:EVMN) Earns Outperform Rating from Royal Bank Of Canada - MarketBeat
RBC Capital Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $48 - Moomoo
Evommune (EVMN) Institutional Ownership 2026 - MarketBeat
Evommune (NYSE:EVMN) Advances Within Biotechnology Research And Development - Kalkine Media
Oppenheimer Initiates Evommune(EVMN.US) With Buy Rating, Announces Target Price $50 - Moomoo
Evommune (NYSE:EVMN) Shares Up 4.7%Here's What Happened - MarketBeat
Oppenheimer Initiates Coverage on Evommune (NYSE:EVMN) - MarketBeat
Evommune Inc (EVMN) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
7.24%
大文字化:
|
ボリューム (24 時間):